Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients (Q35826931)

10 August 2017

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

J H Beijnen

1 reference

10 August 2017

E C M van Gorp

1 reference

10 August 2017

K M L Crommentuyn

1 reference

10 August 2017

B S Kappelhoff

1 reference

10 August 2017

J W Mulder

1 reference

10 August 2017

A T A Mairuhu

1 reference

10 August 2017

P L Meenhorst

1 reference

10 August 2017

A D R Huitema

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

378-389

1 reference

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Genetic contribution to variable human CYP3A-mediated metabolism

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

The importance of modeling interoccasion variability in population pharmacokinetic analyses

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

11 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02455.X

The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884825

Lopinavir/ritonavir: a review of its use in the management of HIV infection

24 September 2018

1 reference

12 December 2020

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins

1 reference

12 December 2020

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects

1 reference

12 December 2020

10.1111/J.1365-2125.2005.02455.X

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

16187970

1 reference